Company Analysis
Sign in

Tonix Pharmaceuticals Holding Corp. (TNXP)

Nasdaq: TNXP · Pharmaceutical Preparations · Berkeley Heights, NJ · filing with the SEC since 2008
Full chart Alerts Compare
Grade4.6
◀ Past 3.4● Present 5.3▶ Future 4.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tonix Pharmaceuticals Holding Corp.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 4 in 2024 and 1 in 2023
Applications published
37
7 of them in 2025
Names they are printed under
6
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Organic fine chemistry1
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
TONIX PHARMACEUTICALS HOLDING CORP its own name
US, as the owner printed on each patent
6 granted
11 published
TONIX PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
TONIX PHARMA LIMITED a subsidiary
named as the applicant on its applications, in IE
0 granted
7 published
TONIX PHARMACEUTICALS HOLDING CORP. its own name
named as the applicant on its applications, in US
0 granted
7 published
TONIX MEDICINES, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Tonix Medicines, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Names not counted (2)
Tonix Pharma Limited
Most of its patents print BM; this name counts in IE. 22 granted and 3 published under it are not counted.
Tonix Pharma Holdings Limited
Most of its patents print BM; this name counts in IE. 0 granted and 24 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 3, 202412,156,864Analogs of cyclobenzaprine and amitryptilenePharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP
Sep 24, 202412,097,183Pharmaceutical composition for treating migrainePharmaceuticalsTonix Medicines, Inc.
Sep 17, 202412,090,139Formulations comprising triptan compoundsPharmaceuticalsTonix Medicines, Inc.
Apr 30, 202411,970,554Labeled oxytocin and method of manufacture and useAnalysis of biological materialsTONIX PHARMACEUTICALS HOLDING CORP
Jan 31, 202311,566,032Radio-protective and chemo-protective substituted thiolsOrganic fine chemistryTONIX PHARMACEUTICALS HOLDING CORP
Dec 6, 202211,517,557Analogs of cyclobenzaprine and amitriptylinePharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP
Jul 19, 202211,389,473Magnesium-containing oxytocin formulations and methods of usePharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP
Jul 9, 20138,481,599Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholismPharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360093EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDEPharmaceuticalsTONIX PHARMA LIMITED
Oct 16, 20252025/0322926EARLY ONSET RESPONSE, FAVORABLE TOLERABILITY, AND SIDE EFFECT PROFILE IN THE TREATMENT OF FIBROMYALGIAPharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP.
Oct 16, 20252025/0319153MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USEPharmaceuticalsTONIX PHARMA LIMITED
Jun 19, 20252025/0195470FORMULATIONS COMPRISING TRIPTAN COMPOUNDSPharmaceuticalsTONIX MEDICINES, INC.
Mar 6, 20252025/0073204ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENEPharmaceuticalsTONIX PHARMACEUTICALS HOLDING CORP
Feb 6, 20252025/0041274METHODS OF TREATING MIGRAINEPharmaceuticalsTONIX MEDICINES, INC.
Jan 16, 20252025/0017902PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINEPharmaceuticalsTONIX MEDICINES, INC.
Dec 19, 20242024/0415789CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTSPharmaceuticalsTONIX PHARMACEUTICALS, INC.
Sep 12, 20242024/0301004LABELED OXYTOCIN AND METHOD OF MANUFACTURE AND USEAnalysis of biological materialsTONIX PHARMACEUTICALS HOLDING CORP. · patent 12,466,855 granted from it
May 23, 20242024/0165126TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDERPharmaceuticalsTONIX PHARMA LIMITED
What it applied for, 2024 to 2025: Pharmaceuticals 12 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TNXP · research, not advice